The Surprising Link Between BRCA Mutations and Prostate Cancer

Scientists have wondered why different cancers develop early in the same individual or family. After an article describing early-onset inherited breast-ovarian cancer appeared in Science in 1990, discoveries followed in 1994 of BRCA1 and in 1995 of BRCA2. As research increased, individuals with damaged forms of these proteins were found to have increased risks not only of breast and ovarian cancer but also pancreatic cancer and, in men, prostate cancer as an additional risk.
The BRCA gene takes its name from the English abbreviation for breast cancer. Proteins called BRCA 1 and 2 repair DNA, which forms our genes. These proteins are tumor suppressor (growth-inhibiting) genes. When defective, DNA cannot be repaired and cancer development begins through damaged DNA. When this main repair route fails, a second tumor cell repair pathway, polymerase (PARP), becomes more active. Suppressing PARP kills cancer cells, so drugs developed against this pathway form targeted treatment for patients with BRCA 1-2 mutations. Drugs in this group include Olaparib, Veliparib and Niraparib.
For ovarian cancer with damaged BRCA1-2 genes, FDA (United States Food and Drug Administration) approval in 2014 was granted to Olaparib (Lynparza) , which demonstrated similar success in studies of breast and prostate cancers with damaged BRCA1-2 genes. A study published in the prestigious NEJM included 49 patients with hormone-resistant prostate cancer.
All had received chemotherapy and all had DNA repair pathway damage (%50 had BRCA2 mutations). Compared with placebo (the group receiving no drug), olaparib provided an additional 6 months of overall survival. Although not yet FDA-approved for prostate cancer, it has become a promising drug for our patients.
Veliparib, in a phase II study presented at the 2016 American Cancer Congress (ASCO), included 153 hormone-resistant prostate cancer patients. It was added to abiraterone (zytiga), used for advanced prostate cancer. Regardless of DNA damage status, veliparib increased time to progression and reduced PSA (prostate-specific antigen). In the subgroup with damaged DNA repair proteins, success was greater, with an additional %45 contribution to disease response and a %90 PSA response. Veliparib also appears likely to have a future role for our advanced prostate cancer patients. Nirapanib , our PARP pathway inhibitor, remains under investigation.
In conclusion, although these drugs demonstrating targeted treatment success have not yet entered everyday practice, they offer promising treatment options for our patients.
Sources
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
N Engl J Med 2016; 375:443-453August 4, 2016DOI: 10.1056/NEJMoa1603144
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.